Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19

Completed

• Conditions: COVID-19 Pneumonia

• Registration Number: NCT04610554
• Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Brief Summary

Infection with severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) may be associated with diffuse alveolar damage and pulmonary vasculitis. Thus, it is likely that pulmonary function changes may be seen in COVID-19 survivors. The aim of the present study was to test that simultaneously-determined lung diffusing capacity for nitric oxide and carbon monoxide may be useful to detect post-viral diffusive gas exchange abnormalities early after mild-to-severe COVID-19-related pneumonias.

Detailed Description

Infection with severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) may be asymptomatic or associated with life-threatening interstitial pneumonia. Clinically, patients affected from severe coronavirus disease-19 (COVID-19) are described as exhibiting rapidly progressing acute respiratory failure with unusually low oxygen levels in arterial blood. On computed tomography scans, diffuse, peripheral "ground glass" opacities of the lung are seen while autopsy lung specimens showed diffuse alveolar damage and capillary endothelialitis.

The objective of the current study, conducted in patients who had recovered from mild-to-severe COVID-19 illness, was to test that simultaneously-determined lung diffusing capacity for nitric oxide (NO) and carbon monoxide (CO) may be of great use to early detect post-infective diffusive gas exchange abnormalities. More specifically, we hypothesized that measurement of membrane diffusive conductance for CO and pulmonary capillary volume may provide accurate information on residual changes of peripheral gas exchanging units of the lung related to previous SARS-CoV-2 infection.

Study Timeline

• Study Start: 2020-05-14
• Status Verified: 2020-10
• Primary Completion: 2020-10-12
• Study Completion: 2020-10-12
• Study First Submitted: 2020-10-29
• Study First Submitted QC: 2020-10-29
• Last Update Submitted: 2020-10-29
• Study First Posted: 2020-10-30
• Last Update Posted: 2020-10-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

• subjects were selected after two nasopharyngeal swabs negative for SARS-CoV-2

Exclusion Criteria

• severe comorbidities potentially affecting pulmonary gas exchange

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Lung diffusing capacity for nitric oxide (DLNO)	At a time interval ranging from 15 to 189 days after two nasopharyngeal swabs negative for SARS-CoV-2	Changes of DLNO after SARS-CoV-2 infection

Secondary Outcome Measures

Name	Time	Method
Lung diffusing capacity for carbon monoxide (DLco)	At a time interval ranging from 15 to 189 days after two nasopharyngeal swabs negative for SARS-CoV-2	Changes of DLco after SARS-CoV-2 infection

Trial Locations

Locations (1)

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro; 🇮🇹 Genoa, Italy